Vision Loss and Substance Misuse: A Systematic Review.

Subst Use Misuse

Department of Population and Public Health Sciences, Wright State Boonshoft School of Medicine, Fairborn, Ohio, USA.

Published: October 2024

The number of people in the U.S. affected by sensory disabilities and/or substance use has continued to increase, but the relationship between them has yet to be fully understood. The purpose of this review is to assess the relationship between substance use and vision loss in the U.S. as described by current literature.  A search of published literature was conducted across MEDLINE, APA PsycINFO, Web of Science, and EBSCO: Psychology and Behavioral Sciences Collection, and CINAHL following the Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) protocol. Risk of bias was assessed by the authors based on study design. U.S. based studies written in English between 2010 and 2022 that reported on vision loss and substance use were included.  In all, 21 articles were included (case reports 11, case series 1, cross-sectional 4, retrospective cohort 3, review 2) representing 89,132 patients. Nineteen studies found a positive association between vision loss and substance use, with 15 studies suggesting substance use was a risk factor for vision loss. One study reported on vision loss preceding substance use but was inconclusive.  Our findings suggest that substance use may be a risk factor for vision loss, and we recommend that providers screen for vision loss in at risk patients to mitigate further disability. Further research is needed to assess the impact visual disabilities may have on substance use, and stronger evidence is needed to verify if substance use is truly a risk factor for vision loss.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10826084.2024.2392561DOI Listing

Publication Analysis

Top Keywords

vision loss
36
loss substance
12
substance risk
12
risk factor
12
factor vision
12
substance
10
vision
9
loss
8
reported vision
8
risk
5

Similar Publications

We report a rare case of a missed intracavernous internal carotid artery dissecting aneurysm occurring as a complication of the base of skull fracture with severe brain injury causing acute cavernous sinus syndrome with permanent vision loss. A 31-year-old Myanmar lady had an alleged motor vehicle accident and suffered severe traumatic brain injury with multiple intracranial bleeds, multiple facial bone and base of skull fractures, and limb fractures. At one week post-trauma, she had severe right eye proptosis with vision loss, ophthalmoplegia, chemosis, and high intraocular pressure.

View Article and Find Full Text PDF

This study details two cases of traumatic cataracts with a history of blunt trauma. Both presented with progressive vision loss, mydriasis, and zonular dialysis. The surgical intervention involved complete cataractous lens removal, anterior vitrectomy, iris cerclage with 10-0 prolene sutures, and retropupillary iris-claw lens fixation.

View Article and Find Full Text PDF

A retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience.

Brachytherapy

January 2025

Ocular Oncology and Radiology Department, S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.

Purpose: To retrospectively evaluate the efficacy of plaque brachytherapy for the treatment of retinoblastoma.

Methods: We retrospectively reviewed the clinical records of 163 patients (186 eyes, 333 tumors) treated with brachytherapy (Ru or Sr plaques) for intraocular retinoblastoma between November 2007 and August 2023.

Results: Complete tumor control was achieved in 273 tumors (82%).

View Article and Find Full Text PDF

"Blindness" is not a contraindication for voretigene neparvovec-rzyl treatment-a review of 9 cases.

Can J Ophthalmol

January 2025

Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Objective: Biallelic RPE65 pathogenic variants may cause Leber congenital amaurosis (LCA). Voretigene neparvovec-rzyl (VN, Luxturna) is the only approved subretinal gene therapy that demonstrated benefit and safety. The eligibility criteria are vague and variable between centres.

View Article and Find Full Text PDF

Diabetic retinopathy (DR) is a serious diabetes complication that can lead to vision loss, making timely identification crucial. Existing data-driven algorithms for DR staging from digital fundus images (DFIs) often struggle with generalization due to distribution shifts between training and target domains. To address this, DRStageNet, a deep learning model, was developed using six public and independent datasets with 91,984 DFIs from diverse demographics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!